Laurus Labs FY26 Revenue ₹6,813 Cr, Up 23%; Net Profit ₹889 Cr, Up 148%
Laurus Labs reported FY26 revenue of ₹6,813 Cr (up 23%) and EBITDA of ₹1,826 Cr (up 64%) with margins at 26.8%. Net profit surged 148% to ₹889 Cr. Q4 FY26 revenue was ₹1,812 Cr (up 5%) with EBITDA at ₹523 Cr. The company declared an interim dividend of ₹1.2 per share.
Significant growth in key financial metrics like revenue, EBITDA, and net profit, coupled with margin expansion and future growth plans involving increased CAPEX, suggests a substantial positive impact on the company's financial standing and investor outlook.
The company reported strong year-on-year growth in revenues, EBITDA, and net profit, along with improved margins and declaration of a dividend, indicating a positive financial performance.
Laurus Labs Limited announced its financial results for the fourth quarter and full year ended March 31, 2026. The company reported a significant increase in performance, with full-year revenues reaching ₹6,813 crore, a 23% rise compared to the previous year. EBITDA for the full year stood at ₹1,826 crore, marking a substantial 64% growth and achieving margins of 26.8%, an improvement of over 6.7 percentage points from FY25. Gross margins also expanded by over 5.0 percentage points to 60.4% due to a favorable product mix.
For the fourth quarter of FY26, revenues were ₹1,812 crore, a 5% increase year-on-year, with EBITDA growing by 10% to ₹523 crore, resulting in robust EBITDA margins of 28.9%. Net profit for the full year FY26 surged by 148% to ₹889 crore, while diluted Earnings Per Share (EPS) increased by 148% to ₹16.4 from ₹6.6 in the previous year. The company declared a second interim dividend of ₹1.2 per share during Q4 FY26.
The CDMO division showed strong growth, with revenues up 36% to ₹2,080 crore for the full year, driven by small molecules and a significant 124% increase in the Bio segment in Q4. The Affordable Medicines (Generics) division reported revenues of ₹4,733 crore, an 18% increase year-on-year, primarily supported by volume growth in the ARV portfolio and ramp-up of select molecules in the US and EU regions.
Laurus Labs plans to increase CAPEX intensity over FY27-28 to support growth projects across small molecule (Human & Animal health), Fermentation, Peptides, and Gene therapy/ADC. The company is committed to its ESG initiatives and has been listed in the S&P Global Sustainability Yearbook for consecutive years. An earnings conference call was scheduled for April 30, 2026, at 5:00 p.m. IST to discuss the results.
What to do with a filing like this
Laurus Labs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Laurus Labs Limited. Read the original for the full detail.